Peginterferon alfa-2b/Ribavirin (Merck & Co)

聚乙二醇干扰素α-2b/利巴韦林

Report date: 2022/01/14 13:23:58

Base Information

Drug NamePeginterferon alfa-2b/Ribavirin (Merck & Co)

Drug Alias NamePEG interferon-alpha-2b + RibavirinPegylated interferon-alpha-2b + RibavirinRibavirin + Peginterferon alfa-2bCotronak + Peginterferon alfa-2bPEG-Intron + REBETOL +[7]

ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines

Mechanisms of ActionInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitorsImmunostimulantsInnate antiviral immune response inducers +[6]

TargetsInosine-5'-monophosphate dehydrogenase (IMPDH)Interferon alpha/beta receptorBacterial DNA-directed RNA polymerase +[4]

Therapy Area/IndicationsHepatitis C

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsYes Ribavirin Peginterferon alfa-2b (Merck Sharp & Dohme)

Global Highest StatusApproved

Highest Status in ChinaN/A

Originator CompaniesMerck & Co Inc

China Registration ClassN/A

Develop Information

Active CompaniesMerck Sharp & Dohme Corp

Inactive CompaniesN/A

Active IndicationsHepatitis C

Inactive IndicationsN/A

Other Information

ATC CodeL03AB